Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Исследование по оценке эффективности и безопасности крема руксолитиниб у участников с узловатой почесухой (PN) (TRuE-PN2)

15 октября 2026 г. обновлено: Incyte Corporation

Фаза 3, двойное слепое, рандомизированное, контролируемое транспортным средством исследование эффективности и безопасности крема руксолитиниб у участников с узловатой почесухой

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

Обзор исследования

Статус

Завершенный

Подробное описание

The study comprises of a 12 week double-blind, vehicle-controlled (DBVC) treatment period, followed by a 40 week open label extension period, and 30 day safety follow-up period During the double blind period, all PN-affected areas identified at baseline will be treated, and during the open label period, only active PN-affected areas will be treated.

Тип исследования

Интервенционный

Регистрация (Действительный)

190

Фаза

  • Фаза 3

Расширенный доступ

Одобренный для продажи населению. См. запись расширенного доступа.

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

      • Phillip, Австралия, 02606
        • Paratus Clinical Research, Woden
    • New South Wales
      • Kogarah, New South Wales, Австралия, 02217
        • Premier Specialists Pty Ltd
      • Liverpool, New South Wales, Австралия, 02170
        • Liverpool Hospital
      • Sydney, New South Wales, Австралия, 02010
        • Holdsworth House Medical Practice
      • Sydney, New South Wales, Австралия, 02145
        • Westmead Hospital
    • Queensland
      • Woolloongabba, Queensland, Австралия, 04102
        • Veracity Clinical Research
    • Victoria
      • Melbourne, Victoria, Австралия, 03004
        • The Alfred Hospital
      • Graz, Австрия, 08036
        • Landeskrankenhaus Universitatsklinikum Graz
      • Linz, Австрия, 04020
        • Ordensklinikum Linz Gmbh Elisabethinen
      • Vienna, Австрия, 01220
        • Sozialmedizinisches Zentrum Ost-Donauspital
      • Pleven, Болгария, 05800
        • Medical Center Medconsult Pleven Ood
      • Rousse, Болгария, 07000
        • Medical Center- Prolet Ltd
      • Sevlievo, Болгария, 05400
        • Medical Center Unimed Eood
      • Sofia, Болгария, 01431
        • Dcc 'Alexandrovska', Eood
      • Sofia, Болгария, 01510
        • Medical Center Hera Eood
      • Stara Zagora, Болгария, 06000
        • Umhat Prof. Dr. Stoyan Kirkovich Ad
      • Bielefeld, Германия, 33647
        • Klinikum Bielefeld Rosenhohe Dermatologie
      • Frankfurt am Main, Германия, 60590
        • Universitatsklinikum Frankfurt
      • Göttingen, Германия, 37075
        • Universitatsmedizin Goettingen
      • Mahlow, Германия, 15831
        • Dermatologische Gemeinschaftspraxis Mahlow
      • Münster, Германия, 48149
        • Universitatsklinikum Munster
      • Hellerup, Дания, 02900
        • Herlev Og Gentofte Hospital
      • Roskilde, Дания, 04000
        • Sjaellands Universitetshospital
      • Badalona, Испания, 08916
        • Ceim Hospital Universitari Germans Trias I Pujol
      • Las Palmas de Gran Canaria, Испания, 35010
        • Hospital Universitario de Gran Canaria Doctor Negrin
      • Madrid, Испания, 28041
        • Hospital Universitario 12 de Octubre
      • Madrid, Испания, 28034
        • Hospital Universitario Ramon Y Cajal
      • Santiago de Compostela, Испания, 15002
        • Clinica Gaias Santiago
      • Milan, Италия, 20122
        • Fondazione Irccs Ca Granda Ospedale Maggiore
      • Naples, Италия, 80131
        • Universita Degli Studi Della Campania Luigi Vanvitelli
      • Perugia, Италия, 06132
        • Azienda Ospedaliera Di Perugia - Ospedale Santa Maria Della Misericordia
      • Pisa, Италия, 56126
        • Azienda Ospedaliero Universitaria Pisana - Ospedale S. Chiara
      • Rome, Италия, 00133
        • Azienda Ospedaliera Universitaria Policlinico Tor Vergata
    • Ontario
      • Etobicoke, Ontario, Канада, M8X 1Y9
        • Kingsway Clinical Research
      • Markham, Ontario, Канада, L3P 1X3
        • Lynderm Research Inc
      • North YORK, Ontario, Канада, M2M 4J5
        • North York Research Inc.
      • Peterborough, Ontario, Канада, K9J 5K2
        • Skin Centre For Dermatology
    • Quebec
      • Québec, Quebec, Канада, G1V 4T3
        • Diex Recherche Quebec Inc.
      • Krakow, Польша, 31-559
        • Diamond Clinic Specjalistyczne Poradnie Lekarskie
      • Lodz, Польша, 90-436
        • Dermoklinika Centrum Medyczne S.C., M. Kierstan, J. Narbutt, A. Lesiak
      • Lublin, Польша, 20-362
        • Luxderm Specjalistyczny Gabinet Dermatologiczny
      • Malbork, Польша, 82-200
        • Centrum Badawcze Panaceum Agnieszka Brzezicka, Magdalena Lenkiewicz Sp. Z O.O.
      • Poznan, Польша, 60-529
        • Solumed Centrum Medyczne
      • Wroclaw, Польша, 50-414
        • Dermaceum Centrum Badan Klinicznych
      • Wroclaw, Польша, 51-318
        • Dermmedica Sp. Z O.O.
    • Alabama
      • Birmingham, Alabama, Соединенные Штаты, 35233
        • University of Alabama At Birmingham
    • Arkansas
      • Arkansas City, Arkansas, Соединенные Штаты, 72758
        • Northwest Arkansas Clinical Trials Center
    • California
      • Los Angeles, California, Соединенные Штаты, 90045
        • Dermatology Research Associates
      • Santa Monica, California, Соединенные Штаты, 90404
        • Clinical Science Institute Clinical Research Specialists Inc
      • Sherman Oaks, California, Соединенные Штаты, 91403
        • Cura Clinical Research
    • Florida
      • Orlando, Florida, Соединенные Штаты, 32819
        • Ars - Maitland Clinical Research Unit
    • Georgia
      • Marietta, Georgia, Соединенные Штаты, 30060-1047
        • Marietta Dermatology the Skin Cancer Center Marietta
    • Indiana
      • South Bend, Indiana, Соединенные Штаты, 46617
        • The South Bend Clinic Main Campus
    • Maryland
      • Baltimore, Maryland, Соединенные Штаты, 21237
        • Axon Clinical Research
    • Massachusetts
      • Beverly, Massachusetts, Соединенные Штаты, 01915
        • Activmed Practices Research, Llc Beverly
    • Ohio
      • Athens, Ohio, Соединенные Штаты, 45701
        • Oakview Dermatology
      • Dublin, Ohio, Соединенные Штаты, 43016
        • Aventiv Research Inc-Dublin
      • Fairborn, Ohio, Соединенные Штаты, 45324
        • Wright State Physicians, Inc.
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Соединенные Штаты, 15232
        • University of Pittsburgh Medical Center Upmc Dermatology Clinic Oakland Falk Medical Building
      • Sugarloaf, Pennsylvania, Соединенные Штаты, 18249
        • Dermdox Center For Dermatology
    • Texas
      • Austin, Texas, Соединенные Штаты, 78759
        • Dermresearch, Inc.
      • Bordeaux, Франция, 33000
        • Bordeaux Chu Hopital Saint - Andre
      • Dijon, Франция, 21000
        • Chu Dijon-Bourgogne
      • Lyon, Франция, 69003
        • Hopital Edouard Herrio
      • Nice, Франция, 06200
        • Chu de Nice - Hospital L Archet
      • Poitiers, Франция, 86021
        • Centre Hospitalier Universitaire de Poitiers
      • Salouël, Франция, 80480
        • Chu Amiens - Hopital Sud
      • Buochs, Швейцария, 06374
        • Dermatology & Skin Care Clinic
      • Lausanne, Швейцария, 01011
        • Centre Hospitalier Universitaire Vaudois (Chuv)
      • Zurich-flughafen, Швейцария, 08058
        • Universitatsspital Zurich
      • Seoul, Южная Корея, 03080
        • Seoul National University Hospital
      • Seoul, Южная Корея, 05505
        • Asan Medical Center
      • Seoul, Южная Корея, 02841
        • Korea University Anam Hospital
      • Seoul, Южная Корея, 08308
        • Korea University Guro Hospital
      • Seoul, Южная Корея, 06591
        • The Catholic University of Korea Seoul St. Mary'S Hospital
      • Suwon, Южная Корея, 16499
        • Ajou University Hospital

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

От 18 лет до 99 лет (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  • Clinical diagnosis of PN ≥ 3 months before screening.
  • ≥ 6 pruriginous lesions on ≥ 2 different body areas (such as right and left leg) at screening and baseline having a treatment area <20% BSA.
  • IGA-CPG-S score of ≥ 2 at screening and baseline.
  • Baseline PN-related WI-NRS score ≥ 7.
  • Willingness to avoid pregnancy or fathering children.

Exclusion Criteria:

  • Chronic pruritus due to a condition other than PN

  • Total estimated BSA treatment area (excluding the scalp) > 20%.

  • Neuropathic and psychogenic pruritus

  • Active atopic dermatitis lesions within 3 months of screening and baseline.

  • Uncontrolled thyroid function

  • Concurrent skin or other serious or unstable medical conditions which may interfere with the evaluation of PN such as immunocompromised status, acute/chronic infections, active malignancy, history of TB, history of DVT/VTE, etc Protocol defined abnormal laboratory results.

  • Use of any protocol-defined prohibited medication unless a washout is completed or use of medication known to cause itching.

  • Psoralen and ultraviolet A or ultraviolet B therapy within 4 weeks before baseline or Ultraviolet light therapy or prolonged exposure to natural or artificial sources of ultraviolet radiation (within 2 weeks before baseline

  • Pregnant or lactating, or considering pregnancy.

  • History of alcoholism or drug addiction within 1 year

  • Known allergy or reaction to any of the components of the study drug.

  • Committed to a mental health institution by virtue of an order issued either by the judicial or the administrative authorities.

  • Employees of the sponsor or investigator or otherwise dependents of them.

  • The following participants are excluded in France:

    1. Vulnerable populations according to article L.1121-6 of the French Public Health Code.
    2. Adults under legal protection or who are unable to express their consent per article L.1121-8 of the French Public Health Code.
    3. Individuals not affiliated with the social security system.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Четырехместный

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Ruxolitinib 1.5% Cream

Participants apply ruxolitinib 1.5% cream topically to the affected areas as a thin film BID for 12 weeks during the DBVC period. Participants who have completed the treatment during DBVC period will enter the open label extension (OLE) period for up to 40 weeks.

Ruxolitinib cream 1.5% twice daily (BID) during the continuous and open label treatment period.

Другие имена:
  • INCB018424 фосфатный крем
  • Опзелура
Плацебо Компаратор: Vehicle Cream

Participants apply ruxolitinib matching vehicle cream topically to the affected areas as a thin film twice daily (BID) for 12 weeks during the DBVC period. Participants who have completed the treatment during DBVC period will enter the open label extension (OLE) period for up to 40 weeks.

Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle-controlled period.

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
WI-NRS4 Response at Week 12
Временное ограничение: Baseline; Week 12

WI-NRS4 was defined as the percentage of participants achieving a ≥4-point improvement (reduction) in Worst-Itch Numeric Rating Scale (WI-NRS) score from baseline. The WI-NRS is a patient-reported outcome comprised of a single item rated on a scale from 0 ("no itch") to 10 ("worst imaginable itch"). Participants assessed their worst level of prurigo nodularis-related itch during the past 24 hours on a scale of 0 to 10. The WI-NRS score for baseline was determined by averaging the 7 daily WI-NRS scores before Day 1 (i.e., Days -7 to -1). The by-visit WI-NRS score for post-baseline visits was determined by averaging the 7 daily WI-NRS scores before the visit day. Participants with missing Week 12 data for any reason, including treatment discontinuation (due to development of atopic dermatitis lesions or any other cause), were defined as nonresponders.

Baseline; Week 12

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
WI-NRS4 Response at Week 4
Временное ограничение: Baseline; Week 4

WI-NRS4 was defined as the percentage of participants achieving a ≥4-point improvement (reduction) in WI-NRS score from baseline. The WI-NRS is a patient-reported outcome comprised of a single item rated on a scale from 0 ("no itch") to 10 ("worst imaginable itch"). Participants assessed their worst level of prurigo nodularis-related itch during the past 24 hours on a scale of 0 to 10. The WI-NRS score for baseline was determined by averaging the 7 daily WI-NRS scores before Day 1 (i.e., Days -7 to -1). The by-visit WI-NRS score for post-baseline visits was determined by averaging the 7 daily WI-NRS scores before the visit day.

Baseline; Week 4
Percentage of Participants With Overall-Treatment Success at Week 12
Временное ограничение: Baseline; Week 12

Overall-Treatment Success was defined as both a WI-NRS4 response and Investigator's Global Assessment for Stage of Chronic Prurigo Treatment Success (IGA-CPG-S-TS). IGA-CPG-S-TS was defined as an IGA-CPG-S score of 0 or 1 with a ≥2 grade improvement from baseline. The IGA-CPG-S is an overall severity rating of chronic prurigo on a scale of 0 to 4: 0, clear (no pruriginous lesions); 1, almost clear (rare palpable pruriginous lesions [approximately 1-5 lesions]); 2, mild (few palpable pruriginous lesions [approximately 6-19 lesions]); 3, moderate (many palpable pruriginous lesions [approximately 20-100 lesions]); 4, severe (abundant palpable pruriginous lesions [over 100 lesions]).

Baseline; Week 12
Percentage of Participants With IGA-CPG-S-TS at Week 12
Временное ограничение: Baseline; Week 12

IGA-CPG-S-TS was defined as an IGA-CPG-S score of 0 or 1 with a ≥2 grade improvement from baseline. The IGA-CPG-S is an overall severity rating of chronic prurigo on a scale of 0 to 4: 0, clear (no lesions); 1, almost clear (rare palpable pruriginous lesions [approximately 1-5 lesions]); 2, mild (few palpable pruriginous lesions [approximately 6-19 lesions]); 3, moderate (many palpable pruriginous lesions [approximately 20-100 lesions]); 4, severe (abundant palpable pruriginous lesions [over 100 lesions]).

Baseline; Week 12
WI-NRS4 Response at Day 7
Временное ограничение: Baseline; Day 7

WI-NRS4 was defined as the percentage of participants achieving a ≥4-point improvement (reduction) in WI-NRS score from baseline. The WI-NRS is a patient-reported outcome comprised of a single item rated on a scale from 0 ("no itch") to 10 ("worst imaginable itch"). Participants assessed their worst level of prurigo nodularis-related itch during the past 24 hours on a scale of 0 to 10. The WI-NRS score for baseline was determined by averaging the 7 daily WI-NRS scores before Day 1 (i.e., Days -7 to -1). The by-visit WI-NRS score for post-baseline visits was determined by averaging the 7 daily WI-NRS scores before the visit day.

Baseline; Day 7
WI-NRS4 Response at Each Post-baseline Visit
Временное ограничение: Baseline; up to Week 52

WI-NRS4 was defined as the percentage of participants achieving a ≥4-point improvement (reduction) in WI-NRS score from baseline. The WI-NRS is a patient-reported outcome comprised of a single item rated on a scale from 0 ("no itch") to 10 ("worst imaginable itch"). Participants assessed their worst level of prurigo nodularis-related itch during the past 24 hours on a scale of 0 to 10. The WI-NRS score for baseline was determined by averaging the 7 daily WI-NRS scores before Day 1 (i.e., Days -7 to -1). The by-visit WI-NRS score for post-baseline visits was determined by averaging the 7 daily WI-NRS scores before the visit day.

Baseline; up to Week 52
DBVC Period: Change From Baseline in WI-NRS Score at Each Post-baseline Visit
Временное ограничение: Baseline; up to Week 12

The WI-NRS is a patient-reported outcome comprised of a single item rated on a scale from 0 ("no itch") to 10 ("worst imaginable itch"). Participants assessed their worst level of prurigo nodularis-related itch during the past 24 hours on a scale of 0 to 10. The WI-NRS score for baseline was determined by averaging the 7 daily WI-NRS scores before Day 1 (i.e., Days -7 to -1). The by-visit WI-NRS score for post-baseline visits was determined by averaging the 7 daily WI-NRS scores before the visit day.

Baseline; up to Week 12
OLE Period: Change From Baseline in WI-NRS Score at Each Post-baseline Visit
Временное ограничение: Baseline; up to Week 52

The WI-NRS is a patient-reported outcome comprised of a single item rated on a scale from 0 ("no itch") to 10 ("worst imaginable itch"). Participants assessed their worst level of prurigo nodularis-related itch during the past 24 hours on a scale of 0 to 10. The WI-NRS score for baseline was determined by averaging the 7 daily WI-NRS scores before Day 1 (i.e., Days -7 to -1). The by-visit WI-NRS score for post-baseline visits was determined by averaging the 7 daily WI-NRS scores before the visit day.

Baseline; up to Week 52
Time to ≥2-point Improvement From Baseline in WI-NRS Score
Временное ограничение: Baseline; up to Week 12

The WI-NRS is a patient-reported outcome comprised of a single item rated on a scale from 0 ("no itch") to 10 ("worst imaginable itch"). Participants assessed their worst level of prurigo nodularis-related itch during the past 24 hours on a scale of 0 to 10. The WI-NRS score for baseline was determined by averaging the 7 daily WI-NRS scores before Day 1 (i.e., Days -7 to -1). The by-visit WI-NRS score for post-baseline visits was determined by averaging the 7 daily WI-NRS scores before the visit day.

Baseline; up to Week 12
Time to ≥4-point Improvement From Baseline in WI-NRS Score
Временное ограничение: Baseline; up to Week 12

The WI-NRS is a patient-reported outcome comprised of a single item rated on a scale from 0 ("no itch") to 10 ("worst imaginable itch"). Participants assessed their worst level of prurigo nodularis-related itch during the past 24 hours on a scale of 0 to 10. The WI-NRS score for baseline was determined by averaging the 7 daily WI-NRS scores before Day 1 (i.e., Days -7 to -1). The by-visit WI-NRS score for post-baseline visits was determined by averaging the 7 daily WI-NRS scores before the visit day.

Baseline; up to Week 12
DBVC Period: Percentage of Participants With a ≥2-point Improvement (Reduction) in Skin Pain NRS Score From Baseline
Временное ограничение: Baseline; up to Week 12

Participants assessed their worst level of prurigo nodularis-related skin pain during the past 24 hours on a scale of 0 ("no pain") to 10 ("worse imaginable pain"). The Skin Pain NRS score for baseline was determined by averaging the 7 daily NRS scores before Day 1 (i.e., Days -7 to -1). The by-visit Skin Pain NRS score for post-baseline visits was determined by averaging the 7 daily NRS scores before the visit day.

Baseline; up to Week 12
OLE Period: Percentage of Participants With a ≥2-point Improvement (Reduction) in Skin Pain NRS Score From Baseline
Временное ограничение: Baseline; up to Week 52

Participants assessed their worst level of prurigo nodularis-related skin pain during the past 24 hours on a scale of 0 ("no pain") to 10 ("worse imaginable pain"). The Skin Pain NRS score for baseline was determined by averaging the 7 daily NRS scores before Day 1 (i.e., Days -7 to -1). The by-visit Skin Pain NRS score for post-baseline visits was determined by averaging the 7 daily NRS scores before the visit day.

Baseline; up to Week 52
DBVC Period: Change From Baseline in Skin Pain NRS Score at Each Post-baseline Visit
Временное ограничение: Baseline; up to Week 12

Participants assessed their worst level of prurigo nodularis-related skin pain during the past 24 hours on a scale of 0 ("no pain") to 10 ("worse imaginable pain"). The Skin Pain NRS score for baseline was determined by averaging the 7 daily NRS scores before Day 1 (i.e., Days -7 to -1). The by-visit Skin Pain NRS score for post-baseline visits was determined by averaging the 7 daily NRS scores before the visit day. Change from baseline was calculated as the post-baseline value minus the baseline value.

Baseline; up to Week 12
OLE Period: Change From Baseline in Skin Pain NRS Score at Each Post-baseline Visit
Временное ограничение: Baseline; up to Week 52

Participants assessed their worst level of prurigo nodularis-related skin pain during the past 24 hours on a scale of 0 ("no pain") to 10 ("worse imaginable pain"). The Skin Pain NRS score for baseline was determined by averaging the 7 daily NRS scores before Day 1 (i.e., Days -7 to -1). The by-visit Skin Pain NRS score for post-baseline visits was determined by averaging the 7 daily NRS scores before the visit day. Change from baseline was calculated as the post-baseline value minus the baseline value.

Baseline; up to Week 52
Percentage of Participants With IGA-CPG-S-TS at Each Postbaseline Visit
Временное ограничение: Baseline; up to Week 52

IGA-CPG-S-TS was defined as an IGA-CPG-S score of 0 or 1 with a ≥2 grade improvement from baseline. The IGA-CPG-S is an overall severity rating of chronic prurigo nodularis on a scale of 0 to 4: 0, clear (no lesions); 1, almost clear (rare palpable pruriginous lesions [approximately 1-5 lesions]); 2, mild (few palpable pruriginous lesions [approximately 6-19 lesions]); 3, moderate (many palpable pruriginous lesions [approximately 20-100 lesions]); 4, severe (abundant palpable pruriginous lesions [over 100 lesions]).

Baseline; up to Week 52
Percentage of Participants With a IGA-CPG-A Score of 0 or 1 With ≥2-grade Improvement (Reduction) at Each Post-baseline Visit
Временное ограничение: Baseline; up to Week 52

The Investigator Global Assessment for Activity of Chronic Prurigo (IGA-CPG-A) is an overall severity rating of chronic prurigo nodularis on a scale of 0 to 4: 0, clear (no pruriginous lesions have excoriations or crusts); 1, almost clear (very small proportion of pruriginous lesions have excoriations or crusts [up to approximately 10% of all pruriginous lesions]); 2, mild (minority of pruriginous lesions have excoriations or crusts [approximately 11%-25% of all pruriginous lesions]); 3, moderate (many pruriginous lesions have excoriations or crusts [approximately 26%-75% of all pruriginous lesions]); 4, severe (majority of pruriginous lesions have excoriations or crusts [approximately 76%-100% of all pruriginous lesions]).

Baseline; up to Week 52
DBVC Period: Percentage of Participants With >75% Healed Lesions From Prurigo Activity Score (PAS) at Each Postbaseline Visit
Временное ограничение: Baseline; up to Week 12

The extent and severity of prurigo nodularis was assessed via the PAS (version 1.2). The first 3 items are descriptive of the type, predominant type, distribution, and quantity of pruriginous lesions. The remaining 2 items of the PAS assess disease activity in terms of percentage (i.e., 0%, 1%-25%, 26%-50%, 51%-75%, and 76%-100%) of pruriginous lesions with excoriations/crusts on top (to reflect active scratching) and the percentage (i.e., 100%, 76%-99%, 51%-75%, 26%-50%, and 0%-25%) of healed pruriginous lesions in order to quantify change of prurigo nodularis skin lesions.

Baseline; up to Week 12
OLE Period: Percentage of Participants With >75% Healed Lesions From PAS at Each Postbaseline Visit
Временное ограничение: Baseline; up to Week 52

The extent and severity of prurigo nodularis was assessed via the PAS (version 1.2). The first 3 items are descriptive of the type, predominant type, distribution, and quantity of pruriginous lesions. The remaining 2 items of the PAS assess disease activity in terms of percentage (i.e., 0%, 1%-25%, 26%-50%, 51%-75%, and 76%-100%) of pruriginous lesions with excoriations/crusts on top (to reflect active scratching) and the percentage (i.e., 100%, 76%-99%, 51%-75%, 26%-50%, and 0%-25%) of healed pruriginous lesions in order to quantify change of prurigo nodularis skin lesions.

Baseline; up to Week 52
DBVC Period: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Each Post-baseline Visit
Временное ограничение: Baseline; up to Week 12

The DLQI is a simple, 10-question, validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. Each question was scored as: 3 (very much), 2 (a lot), 1 (a little), 0 (not at all or not relevant). The DLQI total score was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more the quality of life was impaired. Total DLQI scores were categorized as follows: 0 to 1 (no effect), 2 to 5 (small effect), 6 to 10 (moderate effect), 11 to 20 (very large effect), and 21 to 30 (extremely large effect). Change from Baseline was calculated as the post-baseline visit minus the baseline visit.

Baseline; up to Week 12
OLE Period: Change From Baseline in the DLQI Total Score at Each Post-baseline Visit
Временное ограничение: Baseline; up to Week 52

The DLQI is a simple, 10-question, validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. Each question was scored as: 3 (very much), 2 (a lot), 1 (a little), 0 (not at all or not relevant). The DLQI total score was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more the quality of life was impaired. Total DLQI scores were categorized as follows: 0 to 1 (no effect), 2 to 5 (small effect), 6 to 10 (moderate effect), 11 to 20 (very large effect), and 21 to 30 (extremely large effect). Change from Baseline was calculated as the post-baseline visit minus the baseline visit.

Baseline; up to Week 52
DBVC Period: Change From Baseline in European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) Visual Analog Scale (VAS) Score at Each Postbaseline Visit
Временное ограничение: Baseline; up to Week 12

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. The EQ-5D-5L consists of 2 sections: the EQ-5D descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 response levels, which are coded by single-digit numbers: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, 5 = unable to/extreme problems. The EQ VAS records the participant's self-rated health on a vertical VAS (0-100), on which the endpoints are labeled "the best health you can imagine" (100 score) and "the worst health you can imagine" (0 score). Change from Baseline was calculated as the post-baseline value minus the baseline value.

Baseline; up to Week 12
OLE Period: Change From Baseline in EQ-5D-5L VAS Score at Each Postbaseline Visit
Временное ограничение: Baseline; up to Week 52

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. The EQ-5D-5L consists of 2 sections: the EQ-5D descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 response levels, which are coded by single-digit numbers: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, 5 = unable to/extreme problems. The EQ VAS records the participant's self-rated health on a vertical VAS (0-100), on which the endpoints are labeled "the best health you can imagine" (100 score) and "the worst health you can imagine" (0 score). Change from Baseline was calculated as the post-baseline value minus the baseline value.

Baseline; up to Week 52
DBVC Period: Change From Baseline in EQ-5D-5L Dimension Scores at Each Postbaseline Visit
Временное ограничение: Baseline; up to Week 12

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. The EQ-5D-5L consists of 2 sections: the EQ-5D descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 response levels, which are coded by single-digit numbers: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, 5 = unable to/extreme problems. The EQ VAS records the participant's self-rated health on a vertical VAS (0-100), on which the endpoints are labeled "the best health you can imagine" (100 score) and "the worst health you can imagine" (0 score). Change from Baseline was calculated as the post-baseline value minus the baseline value.

Baseline; up to Week 12
OLE Period: Change From Baseline in EQ-5D-5L Dimension Scores at Each Postbaseline Visit
Временное ограничение: Baseline; up to Week 52

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. The EQ-5D-5L consists of 2 sections: the EQ-5D descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 response levels, which are coded by single-digit numbers: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, 5 = unable to/extreme problems. The EQ VAS records the participant's self-rated health on a vertical VAS (0-100), on which the endpoints are labeled "the best health you can imagine" (100 score) and "the worst health you can imagine" (0 score). Change from Baseline was calculated as the post-baseline value minus the baseline value.

Baseline; up to Week 52
DBVC Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
Временное ограничение: up to Week 12

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.

up to Week 12
DBVC Period: Number of Participants With Any ≥Grade 3 TEAE
Временное ограничение: up to Week 12

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug. The severity of TEAEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grades 1 through 5. The investigator made an assessment of intensity for each TEAE and assigned it to one of the following categories: Grade 1, mild; Grade 2, moderate; Grade 3, severe or medically significant but not immediately life threatening; Grade 4, life-threatening consequences; Grade 5, fatal.

up to Week 12
OLE Period: Number of Participants With Any TEAE
Временное ограничение: from beginning of Week 13 up to Week 56

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.

from beginning of Week 13 up to Week 56
OLE Period: Number of Participants With Any ≥Grade 3 TEAE
Временное ограничение: from beginning of Week 13 up to Week 56

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug. The severity of TEAEs was assessed using CTCAE version 5.0 Grades 1 through 5. The investigator made an assessment of intensity for each TEAE and assigned it to one of the following categories: Grade 1, mild; Grade 2, moderate; Grade 3, severe or medically significant but not immediately life threatening; Grade 4, life-threatening consequences; Grade 5, fatal.

from beginning of Week 13 up to Week 56

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

12 июня 2023 г.

Первичное завершение (Действительный)

30 декабря 2024 г.

Завершение исследования (Действительный)

4 ноября 2025 г.

Даты регистрации исследования

Первый отправленный

1 марта 2023 г.

Впервые представлено, что соответствует критериям контроля качества

1 марта 2023 г.

Первый опубликованный (Действительный)

10 марта 2023 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

6 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

15 октября 2026 г.

Последняя проверка

1 октября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Другие идентификационные номера исследования

  • INCB18424-320
  • 2022-502461-23-00 (Идентификатор реестра: EU CT Number)

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

ДА

Описание плана IPD

Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Сроки обмена IPD

Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Критерии совместного доступа к IPD

Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Совместное использование IPD Поддерживающий тип информации

  • STUDY_PROTOCOL
  • САП

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться